<DOC>
	<DOCNO>NCT01214668</DOCNO>
	<brief_summary>The goal study determine dose LY573636 administer safely combination liposomal doxorubicin patient advance cancer fail prior treatment . The study consist dose escalation phase maximum tolerate dose ( MTD ) dose confirmation phase patient platinum resistant epithelial ovarian , fallopian tube primary peritoneal cancer never treat doxorubicin .</brief_summary>
	<brief_title>Dose-Escalation Study LY573636-sodium Liposomal Doxorubicin Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>You must histologically confirm solid malignancy unresectable and/or metastatic progress receive standard approve chemotherapy You must solid malignancy anthracyclinebased regimen felt reasonable treatment option You must measurable disease nonmeasurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) You must serum albumin level great equal 3.0 g/dL ( 30 g/L ) You must performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale You must tumor progression receive standard/approved chemotherapy You must reliable willing make available duration study willing follow study procedure Women must sterile , postmenopausal contraception men must sterile contraception Your test result assess function blood , kidney , liver , heart satisfactory Ovarian patient confirmation phase must fail achieve least partial response firstline platinumbased therapy ( platinumrefractory ) progression le 6 month response firstline platinumbased therapy ( platinumresistant ) Ovarian patient confirmation phase must measurable disease RECIST Ovarian patient confirmation phase must liposomal doxorubicin doxorubicin naive amendable curative therapy You receive investigational drug within last 28 day You ongoing serious illness include active bacterial , fugal , viral infection You current hematologic malignancy , acute chronic leukemia , brain metastasis You currently receive warfarin ( CoumadinÂ® ) therapy You know positive test result human immunodeficiency , hepatitis B surface antigen hepatitis C antibodies You history cardiac disease clinical evidence congestive heart failure Ovarian patient confirmation phase receive 2 cytotoxic regimen platinumresistant disease You currently receive amiodarone , quinidine , propofol , clozapine If take esomeprazole pantoprazole must able stop take medication within 72 hour LY573636 administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>